Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9316039rdf:typepubmed:Citationlld:pubmed
pubmed-article:9316039lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C0042798lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C1556084lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C0032000lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C0028833lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C1096776lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:9316039lifeskim:mentionsumls-concept:C0206012lld:lifeskim
pubmed-article:9316039pubmed:issue4lld:pubmed
pubmed-article:9316039pubmed:dateCreated1997-11-25lld:pubmed
pubmed-article:9316039pubmed:abstractTextThe somatostatin analog octreotide has been demonstrated to improve optic tract compression caused by pituitary macroadenomas within hours of its administration and/or reduce tumor size in some patients. We report the results of a prospective multicenter study of the effects of octreotide on visual function and tumor size in patients with nonfunctioning pituitary adenomas or gonadotropin-secreting adenomas.lld:pubmed
pubmed-article:9316039pubmed:languageenglld:pubmed
pubmed-article:9316039pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316039pubmed:citationSubsetIMlld:pubmed
pubmed-article:9316039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316039pubmed:statusMEDLINElld:pubmed
pubmed-article:9316039pubmed:monthOctlld:pubmed
pubmed-article:9316039pubmed:issn0148-396Xlld:pubmed
pubmed-article:9316039pubmed:authorpubmed-author:MartinDDlld:pubmed
pubmed-article:9316039pubmed:authorpubmed-author:WarnerGGlld:pubmed
pubmed-article:9316039pubmed:authorpubmed-author:HarrisA GAGlld:pubmed
pubmed-article:9316039pubmed:authorpubmed-author:James-Deidier...lld:pubmed
pubmed-article:9316039pubmed:authorpubmed-author:Chaumet-Riffa...lld:pubmed
pubmed-article:9316039pubmed:authorpubmed-author:RenardEElld:pubmed
pubmed-article:9316039pubmed:issnTypePrintlld:pubmed
pubmed-article:9316039pubmed:volume41lld:pubmed
pubmed-article:9316039pubmed:ownerNLMlld:pubmed
pubmed-article:9316039pubmed:authorsCompleteYlld:pubmed
pubmed-article:9316039pubmed:pagination786-95; discussion 796-7lld:pubmed
pubmed-article:9316039pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:meshHeadingpubmed-meshheading:9316039-...lld:pubmed
pubmed-article:9316039pubmed:year1997lld:pubmed
pubmed-article:9316039pubmed:articleTitleA prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group.lld:pubmed
pubmed-article:9316039pubmed:affiliationDepartment of Internal Medicine, Hôpital Lariboisière, Université Paris VII, France.lld:pubmed
pubmed-article:9316039pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9316039pubmed:publicationTypeMulticenter Studylld:pubmed